Aurobindo Pharma, Glenmark, and Zydus recall products in US over mfg issues

Q: How long will it take to read this news story?

The story "Aurobindo Pharma, Glenmark, and Zydus recall products in US over mfg issues" has 398 words across 18 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Aurobindo Pharma, Glenmark, and Zydus recall products in US over mfg issues" was covered 4 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 113 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #24412761</li><li>URL: https://beamstart.com/news/aurobindo-pharma-glenmark-and-zydus-17342510624331</li></ul>

Business Standard Logo Business Standard 4h ago

Aurobindo Pharma, Glenmark, and Zydus recall products in US over mfg issues - Business Standard

Quick Summary:

As per the latest Enforcement Report of US Food and Drug Administration (USFDA), Aurobindo Pharma USA Inc, a subsidiary of Hyderabad-based drug maker, is recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths.

Drug makers Aurobindo Pharma, Glenmark and Zydus are recalling products in the US market due to manufacturing issues, according to the US health regulator.

Similarly, a US-based subsidiary of Glenmark Pharmaceuticals is recalling around 90,000 bottles of Diltiazem Hydrochloride extended-release capsules (multiple strengths) in the US market.